Good
Mostly Aligned
Patient Risk:
Low
Summary
Most statements about additive CNS side effects (dizziness/somnolence) with ethanol are consistent with label language describing additive effects on cognitive/gross motor functioning with ethanol and reported dizziness/somnolence. However, several claims about alcohol not affecting efficacy, specific symptom likelihoods (trouble concentrating, impaired coordination, falls), mechanisms (judging medication efficacy), and timing context (new start after dose increases) are not explicitly supported by the provided label excerpts.
Category Scores
Accurate Statements
Alcohol and pregabalin can both cause effects on the brain and nervous system.
Label 7 notes additive effects on cognitive and gross motor functioning when pregabalin is co-administered with ethanol; label 5.5 reports pregabalin-related dizziness and somnolence.
Using alcohol together with pregabalin can increase the chance of dizziness or lightheadedness.
Label 7: additive effects on cognitive and gross motor functioning with ethanol. Label 5.5: pregabalin may cause dizziness and somnolence.
Using alcohol together with pregabalin can increase the chance of sleepiness or sedation.
Label 7: additive effects on cognitive and gross motor functioning with ethanol. Label 5.5 and 6.1: pregabalin may cause somnolence.
The key issue with alcohol and pregabalin is typically additive side effects rather than loss of drug efficacy.
Label 7 explicitly describes additive effects with ethanol and does not state pharmacokinetic loss of pregabalin efficacy; however, efficacy/non-efficacy is not directly addressed in the excerpts.
Alcohol may increase sedation or impairment beyond what would be expected from pregabalin alone.
Label 7: additive effects on cognitive and gross motor functioning with ethanol, supporting increased impairment/sedation when combined.
The combined effects are more concerning if the patient is also using other medicines that cause sedation, such as opioids or benzodiazepines or other sleep-inducing drugs.
Label 5.4: respiratory depression when co-administered with CNS depressants including opioids. Label 7: additive effects on cognitive/gross motor functioning with ethanol (general additive effects with CNS depressants supported in excerpt context).
The combined effects are more concerning if the patient is newly started on pregabalin or has recently increased the dose.
Label 5.5 and 5.6 describe dizziness/somnolence and need for gradual discontinuation; the provided excerpts do not explicitly mention alcohol risk timing with initiation/dose increases.
Unsupported Statements
There is no strong evidence that alcohol directly cancels or permanently reduces Lyrica (pregabalin) effectiveness.
Provided label excerpts do not address whether alcohol affects pregabalin efficacy or permanence of effect.
Using alcohol together with pregabalin can increase the chance of impaired coordination and slowed reaction time.
Label 7 supports additive effects on gross motor functioning with ethanol, but the excerpt does not specifically mention impaired coordination or slowed reaction time.
Using alcohol together with pregabalin can increase the chance of trouble concentrating.
Label 7 supports additive effects on cognitive functioning with ethanol, but the excerpt does not specifically mention 'trouble concentrating.'
Alcohol can make it harder to judge how well pregabalin is working for symptoms, even if alcohol does not chemically block the drug’s effect.
No labeling excerpt addresses symptom-tracking, ability to judge treatment response, or assessment impacts from alcohol.
Alcohol use with pregabalin can raise the risk of accidents and falls.
Although label 5.5 notes dizziness/somnolence may impair ability to drive/operate machinery, the excerpts do not explicitly mention accidents or falls.
In response to increased sedation or impairment, patients may take less medicine, stop early, or not tolerate the regimen as prescribed.
No excerpt states patient behavior changes related to alcohol-induced sedation/impairment.
Avoiding alcohol while taking pregabalin is the safest approach, especially when first starting, after dose increases, or if pronounced sleepiness or dizziness occurs.
Label excerpt does not provide an explicit instruction to avoid alcohol, nor does it specify increased risk 'especially when first starting' or 'after dose increases' for alcohol specifically.
If considering alcohol while on pregabalin, it should be discussed with the prescriber because the risk depends on dose and patient response.
Provided excerpts do not include guidance to discuss alcohol with a prescriber, nor do they describe risk as depending on dose/patient response specifically for alcohol.
The combined effects are more concerning if the patient has conditions that already affect balance, alertness, or breathing.
Label 5.4 addresses underlying respiratory impairment in the context of CNS depressants; however, balance/alertness conditions and 'breathing' risk specifically for alcohol + pregabalin are not explicitly stated in the excerpts.
Alcohol is more likely to worsen pregabalin central nervous system side effects than to reduce pregabalin therapeutic effectiveness directly.
The label excerpts support additive cognitive/gross motor impairment with ethanol, but do not directly address alcohol's effect on pregabalin therapeutic effectiveness.
Contradictions
Important Omissions
Label-supported counseling language about dizziness/somnolence and impairment of tasks such as driving/operating machinery when taking pregabalin (including with CNS depressants) is not reflected in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims generally focus on additive impairment (dizziness/somnolence/cognitive/gross motor effects) which is consistent with label excerpts for ethanol co-administration and pregabalin CNS effects. Several additional specifics (falls, accidents, timing guidance, and dosing-dependent discussion advice) are not explicitly supported by the provided label excerpts, reducing labeling fidelity but not introducing clear direct contradictions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several alcohol-specific claims (no effect on efficacy, falls/accidents, inability to judge response, avoidance advice, and dose/timing dependence) are not supported by the provided label excerpts.
Suggested Improvement
Rephrase to align strictly with label-supported points: pregabalin can cause dizziness and somnolence and co-administration with ethanol shows additive effects on cognitive and gross motor functioning; avoid making unsupported claims about efficacy loss, falls/accidents, or specific counseling/timing guidance for alcohol beyond what the label excerpt states (e.g., impairment of tasks such as driving/operating machinery).